Making a Major Impact on B Cell Cancers


Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule specifically designed to degrade Bruton’s Tyrosine Kinase (BTK). The aforementioned study acknowledges Accutar’s success in bringing oral chimeric degraders to the clinic. AC0676 was specifically designed with the goal of degrading both BTK and wild-type BTK mutations.

B cells are critical to the immune system. They neutralize the threat from an infectious agent by producing antibodies that will bind to the antigen of the foreign invader. The B-cell receptor pathway is activated once the antigen binds to a receptor on a B-cell.

The enzyme Bruton’s tyrosine kinase (BTK) is critical in activating the B-cell receptor pathway. The B-cells are unable to function properly without it.

About BTK Inhibitors

BTK inhibitors are drugs that target cancers caused by B cells that are defective, namely B-cell lymphomas, chronic lymphocytic leukemia, and Waldenström macroglobulinemia.

Three BTK inhibitors have had a major impact on multiple B-cell cancers: ibrutinib, pirtobrutinib, and acalabrutinib.

About the AC0676 Trial (NCT05780034)

Accutar Biotechnology is pleased to announce the first patient to be enrolled in its Phase 1 open-label, multi-center trial for the treatment of patients with B-cell malignancies. The study will investigate the tolerability safety, and anti-tumor activity of AC0676 to treat patients who have relapsed or who are refractory to B-cell malignancies. The list includes small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-GCB diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM) and follicular lymphoma (FL).

AC0676 is a degrader of Bruton’s Tyrosine Kinase to potentially treat relapsed/refractory patients who have B-cell malignancies.

Thus far AC0676 has exhibited potent BTK degradation with positive potential for anti-tumor success in animal models.

Accutar Biotechnology is focused on artificial intelligence (AI) empowered drug discovery.

Rose Duesterwald

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email